EE10 Cost-Effectiveness of Pembrolizumab Plus Chemotherapies for First-Line Treatment in Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer (MTNBC) in France
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.264
https://www.valueinhealthjournal.com/article/S1098-3015(22)02468-8/fulltext
Title :
EE10 Cost-Effectiveness of Pembrolizumab Plus Chemotherapies for First-Line Treatment in Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer (MTNBC) in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02468-8&doi=10.1016/j.jval.2022.09.264
First page :
Section Title :
Open access? :
No
Section Order :
12066